Medtide Inc is a China-based company mainly engaged in the contract research, development and manufacturing of peptide. The Company mainly provides contract research organization (CRO) services, namely peptide new chemical entity (NCE) discovery synthesis, contract development and manufacturing organization (CDMO) services, namely peptide chemistry, manufacturing, and control (CMC) development and commercial manufacturing. The Company's services primarily focus on providing customers with active pharmaceutical ingredients (APIs) rather than drug products. The Company also provides customers with peptide drug development, production, and CMC filing support services. The Company mainly operates its business in the domestic market and overseas markets.

Employees

596

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
03/11/26	HK$19.47	+0.52%	210,100
02/11/26	HK$19.37	+1.41%	295,000
30/10/26	HK$19.10	-1.60%	126,700
29/10/26	HK$19.41	-3.05%	88,400
28/10/26	HK$20.02	+3.36%	85,900

Delayed Quote Hong Kong S.E.

More quotes

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

16.56CNY

Average target price

19.66CNY

Spread / Average Target

+18.76%

Consensus

Net sales - Rate of surprise

Rate of surprise - Net sales - Annual - Medtide Inc.

Company calendar

Market Closed - Hong Kong S.E. 08:08:08 03/11/2026 GMT			5-day change	1st Jan Change
19.47 ^HKD	+0.52%		-0.82%	-36.12%

09-24	Medtide Acquires China Land, Property for Peptide CDMO Project	MT
09-24	Medtide Inc. Announces Resignation of Li Lingmei as Executive Director, Effective September 24, 2026	CI

Market Cap	2.35B 2.76B 352M 314M 289M 262M 492M 33.33B 505M 3.45B 1.39B 17.59B 1.32B 1.29B 55.76B	P/E 2026 *	-	P/E 2027 *	-
Enterprise Value	1.77B 2.08B 265M 237M 218M 198M 371M 25.11B 380M 2.6B 1.04B 13.25B 995M 974M 42.01B	EV / Sales 2026 *	2.96x	EV / Sales 2027 *	2.29x
Free-Float	19.48%	Yield 2026 *	-	Yield 2027 *	-

Markets		Quality
Hong Kong S.E.	3880	Delayed
Deutsche Boerse AG	FQ2	Delayed

09-24	Medtide Acquires China Land, Property for Peptide CDMO Project	MT
09-24	Medtide Inc. Announces Resignation of Li Lingmei as Executive Director, Effective September 24, 2026	CI
09-20	Medtide Inc.(SEHK:3880) added to S&P Global BMI Index	CI
08-27	Medtide Inc. Reports Earnings Results for the Half Year Ended June 30, 2026	CI
07-31	Medtide Names CFO	MT
07-31	Medtide Inc. Announces Appointment of Ding Lijun as Chief Financial Officer, Effective July 31, 2026	CI
07-31	Medtide Inc. Announces Management Changes, Effective July 31, 2026	CI
07-31	Medtide Inc. Announces Change of Principal Place of Business in Hong Kong	CI
07-31	Medtide Inc. Provides Group Earnings Guidance for the Six Months Ended Year Ended June 30, 2026	CI
06-30	95,524,875 H Shares of Medtide Inc. are subject to a Lock-Up Agreement Ending on 29-JUN-2026.	CI
06-18	Medtide Inc. Announces Abolishment of the Supervisory Committee	CI
03-30	Medtide Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
03-09	Medtide Completes Hong Kong-Listed Share Full Circulation	MT

Medtide Inc. Share Price

Stocks

3880

CNE100006S86

Biotechnology & Medical Research

Valuation: Medtide Inc.

Chart: Medtide Inc.

Latest news: Medtide Inc.

Press Releases: Medtide Inc.

Quotes and Performance

Price Extremes

Managers and Directors: Medtide Inc.

Latest insider transactions

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Analysts' Consensus

Net sales - Rate of surprise

1 day	+0.52%
1 week	-0.82%
Current month	+1.94%
1 month	-8.07%
3 months	-13.54%
6 months	-9.78%
Current year	-36.12%

1 week	18.03	20.1
1 month	18.03	21.48
Current year	17.64	30.46
1 year	17.64	31.98
3 years	17.64	41.72
5 years	17.64	41.72
10 years	17.64	41.72

Manager	Title	Age	Since
Qi Xu CEO	Chief Executive Officer	58	10/06/2020
Li Jun Ding DFI	Director of Finance/CFO	50	30/07/2026
Wei Qun Xu DFI	Director of Finance/CFO	53	30/09/2020

Director	Title	Age	Since
Qi Xu CHM	Chairman	58	10/06/2020
Xiang Li Li BRD	Director/Board Member	51	26/01/2022
Xiang Li BRD	Director/Board Member	63	26/01/2022

Date	Insider	Type	Main position	Quantity	% Market Cap.
09/03/26	Qi Xu	Other	Chief Executive Officer	68,201,112	48.0967%
09/03/26	Xiang Li Li	Other	Director	68,201,112	48.0967%
09/03/26	Qi Xu	Other	Chief Executive Officer	68,201,112	48.0967%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
MEDTIDE INC.	+0.52%	-0.82%	-36.37%	-	350M
WUXI APPTEC CO., LTD.	-2.43%	-7.34%	+36.10%	+58.44%	62.23B
ARGENX SE	+0.61%	+0.77%	+11.13%	+69.42%	54.92B
LONZA GROUP AG	+0.62%	+2.58%	+20.96%	+98.18%	55.26B
IQVIA HOLDINGS INC.	+1.31%	-3.37%	+22.69%	+33.06%	42.59B
BEONE MEDICINES AG	-1.74%	-2.87%	+14.01%	+93.46%	41.08B
REVOLUTION MEDICINES, INC.	+3.46%	+4.84%	+229.06%	+781.00%	40.33B
GENMAB A/S	+0.57%	+24.09%	+99.46%	+84.11%	33.12B
CELLTRION, INC.	-1.09%	-0.05%	+13.55%	+45.35%	32.61B
INSMED INCORPORATED	-3.38%	+10.96%	-43.42%	+324.02%	23.98B
Average	-0.12%	+3.24%	+36.72%	+176.34%	38.65B
Weighted average by Cap.	-0.10%	+2.11%	+45.22%	+159.68%

	2026 *	2027 *
Net sales	599M 704M 89.7M 80.14M 73.61M 66.85M 126M 8.5B 129M 879M 353M 4.48B 337M 329M 14.21B	742M 873M 111M 99.37M 91.28M 82.9M 156M 10.54B 160M 1.09B 438M 5.56B 417M 409M 17.63B
Net income	-	-
Net Debt	-579M -681M -86.76M -77.51M -71.2M -64.66M -121M -8.22B -124M -850M -342M -4.34B -326M -319M -13.75B	-649M -763M -97.25M -86.88M -79.81M -72.48M -136M -9.21B -140M -953M -383M -4.86B -365M -357M -15.41B